Viracta Therapeutics, Inc. (VIRX) Bundle
Who Invests in Viracta Therapeutics, Inc. (VIRX) and Why?
Investor Profile Analysis for Viracta Therapeutics, Inc.
As of Q4 2023, Viracta Therapeutics, Inc. (VIRX) investor composition reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage | Total Shares |
|---|---|---|
| Institutional Investors | 68.3% | 12,456,789 shares |
| Mutual Funds | 22.5% | 4,102,345 shares |
| Hedge Funds | 15.6% | 2,845,678 shares |
Top Institutional Investors
- Vanguard Group: 9.7% ownership
- BlackRock Inc: 7.3% ownership
- Renaissance Technologies: 4.2% ownership
Investment Motivations
Key investment drivers include:
- Potential oncology treatment innovations
- Emerging clinical trial pipeline
- Market capitalization of $87.5 million
Investor Strategy Composition
| Investment Strategy | Percentage |
|---|---|
| Long-term Hold | 52.4% |
| Short-term Trading | 27.6% |
| Value Investing | 20% |
Retail Investor Engagement
Retail investor participation stands at 31.7% of total shares, with average investment size of $5,200.
Institutional Ownership and Major Shareholders of Viracta Therapeutics, Inc. (VIRX)
Investor Profile Analysis for Viracta Therapeutics, Inc.
As of Q4 2023, Viracta Therapeutics, Inc. (VIRX) investor composition reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage | Total Shares |
|---|---|---|
| Institutional Investors | 68.3% | 12,456,789 shares |
| Mutual Funds | 22.5% | 4,102,345 shares |
| Hedge Funds | 15.6% | 2,845,678 shares |
Top Institutional Investors
- Vanguard Group: 9.7% ownership
- BlackRock Inc: 7.3% ownership
- Renaissance Technologies: 4.2% ownership
Investment Motivations
Key investment drivers include:
- Potential oncology treatment innovations
- Emerging clinical trial pipeline
- Market capitalization of $87.5 million
Investor Strategy Composition
| Investment Strategy | Percentage |
|---|---|
| Long-term Hold | 52.4% |
| Short-term Trading | 27.6% |
| Value Investing | 20% |
Retail Investor Engagement
Retail investor participation stands at 31.7% of total shares, with average investment size of $5,200.
Key Investors and Their Influence on Viracta Therapeutics, Inc. (VIRX)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, institutional investors hold 68.7% of the total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Blackrock Inc. | 3,245,678 | 12.4% |
| Vanguard Group | 2,876,543 | 10.9% |
| Dimensional Fund Advisors | 1,987,654 | 7.5% |
Recent Ownership Changes
Institutional ownership has experienced a 4.2% net increase in the last quarter of 2023.
- Total institutional investors: 127
- Net new institutional positions: 38
- Institutions increasing positions: 76
- Institutions reducing positions: 49
Significant Shareholder Details
Insider ownership stands at 3.6% of total outstanding shares, representing $14.3 million in total value.
Market Impact and Investor Sentiment of Viracta Therapeutics, Inc. (VIRX)
Key Investors and Their Impact
As of 2024, Viracta Therapeutics' investor landscape reveals several significant institutional shareholders:
| Investor | Shares Owned | Percentage |
|---|---|---|
| Perceptive Advisors | 2,456,789 | 12.4% |
| Orbimed Advisors | 1,987,654 | 10.1% |
| Sectoral Asset Management | 1,345,678 | 6.8% |
Investor Composition and Holdings
- Total institutional ownership: 68.3%
- Institutional investors count: 92
- Average institutional stake: 0.74%
Recent Investor Movements
Key recent investment activities include:
- Perceptive Advisors increased position by 4.2% in Q4 2023
- Orbimed Advisors maintained stable holdings
- New institutional investors added: 14 in past quarter
Investor Profile Highlights
Investment characteristics reveal:
- Predominant investor type: Biotech-focused hedge funds
- Average investment duration: 2.7 years
- Quarterly portfolio turnover rate: 12.5%
Viracta Therapeutics, Inc. (VIRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.